cadonilimab
spdr s&p biotech,akesobio,ishares biotechnology
['cadonilimab', '$ibb', '$xbi']
new data on cadonilimab presented at 2023 asco conference shows promising efficacy in pd-l1-negative patients after 2 years of treatment more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt